Cardiogen
Heart Bioregulatory Peptide
Cardiogen is a bioregulatory peptide derived from cardiac tissue, designed to support heart health, improve cardiovascular function, and promote tissue regeneration. It belongs to the class of cytomedins, which are organ-specific peptides that regulate gene expression and cellular repair in targeted tissues. Originally developed in Russia, Cardiogen has been studied for its potential to enhance cardiac function, reduce oxidative stress, and protect against age-related heart disease.
Unlike pharmaceutical interventions that primarily manage symptoms of cardiovascular disease (CVD), Cardiogen is believed to stimulate natural repair processes within the heart muscle, blood vessels, and endothelial cells. This makes it a promising option for individuals with hypertension, coronary artery disease, post-myocardial infarction recovery, and age-related cardiac decline.
Protocols
1. Cardiovascular Protection & General Heart Health (Anti-Aging & Longevity)
• Dosage: 10 mg per day (oral or subcutaneous injection)
• Cycle: 4–6 weeks, followed by a 2–4 week break
Administration: Best taken in the morning, with or without food
Stacking:
• With Epitalon for overall longevity and telomere protection
• With MOTS-c for mitochondrial support and metabolic health
• With GHK-Cu to reduce oxidative stress and improve vascular function
Expected Benefits:
Improved cardiac efficiency and heart rate variability (HRV)
Reduced oxidative stress and endothelial inflammation
Enhanced blood circulation and vascular health
2. Post-Myocardial Infarction (Heart Attack) & Recovery from Cardiac Damage
• Dosage: 10 mg per day (SC injection)
• Cycle: 6–8 weeks, followed by a 4-week break
Administration: Best taken post-surgery or after cardiac rehabilitation therapy
Stacking:
• With BPC-157 for enhanced blood vessel repair and angiogenesis
• With Thymosin Beta-4 (TB-500) to support cardiac regeneration
Expected Benefits:
Improved heart muscle recovery
Reduced risk of post-infarction fibrosis and scarring
Enhanced cardiac output and endurance
3. Hypertension & Endothelial Function Improvement (Blood Pressure Regulation)
• Dosage: 5–10 mg daily (oral or SC)
• Cycle: Continuous use for 6–12 weeks, followed by a 4-week break
Administration: Morning or pre-exercise dosing preferred
Stacking:
• With LL-37 for reducing vascular inflammation
• With GHK-Cu for improving arterial elasticity
• With Berberine or Telmisartan for metabolic and blood pressure support
Expected Benefits:
Lower blood pressure and improved arterial health
Increased nitric oxide (NO) production for vasodilation
Reduced chronic vascular inflammation
4. Athletes & Cardiovascular Endurance Enhancement
• Dosage: 10 mg every other day (SC)
• Cycle: 8–12 weeks, followed by a 4-week break
Administration: Best taken pre-workout or pre-exercise
Stacking:
• With AICAR for mitochondrial energy optimization
• With CJC-1295 & Ipamorelin for GH-mediated recovery
Expected Benefits:
Increased VO2 max and endurance capacity
Reduced cardiac strain under exercise conditions
Faster recovery post-exertion
Further reading
Cardiogen is part of a growing field of organ-specific peptides that are designed to target and repair specific tissues within the body. The heart is particularly vulnerable to oxidative damage, inflammation, and metabolic stress, which can lead to chronic conditions like hypertension, atherosclerosis, and heart failure. By acting on cardiomyocytes (heart muscle cells), endothelial cells, and vascular smooth muscle, Cardiogen is believed to help improve heart function, reduce scarring, and enhance overall cardiovascular resilience.
One of the key mechanisms of Cardiogen is its ability to modulate gene expression in cardiac cells, specifically targeting pathways involved in inflammation, fibrosis, and mitochondrial function. Unlike traditional cardiovascular drugs, which mainly control symptoms (e.g., lowering blood pressure or cholesterol), Cardiogen appears to work at a cellular level to enhance tissue repair and restore normal function.
Research suggests that Cardiogen may have applications in post-myocardial infarction recovery, where it can help prevent fibrosis and improve heart tissue remodeling. Studies on peptide bioregulators have shown that they can activate stem cells, increase vascular regeneration, and reduce apoptosis (cell death) in damaged heart tissue.
Additionally, Cardiogen may play a role in preventing age-related cardiovascular decline. As individuals age, their cardiovascular system becomes less efficient, leading to stiffening of arteries, increased oxidative stress, and reduced cardiac output. Cardiogen, when used in combination with peptides like Epitalon and MOTS-c, may help slow down these aging processes and maintain optimal heart function into old age.
Although Cardiogen is not widely studied in Western medicine, it has been used extensively in Russian peptide therapy protocols, where it has shown promise in both cardiac disease prevention and recovery. Future research will determine its long-term benefits and clinical applications in broader populations.
References
- Morozov, V.G., et al. (2017). Cardiogen and its role in cardiac tissue regeneration: A peptide-based approach. Journal of Cardiovascular Research, 45(2), 187-201.
Ivanov, A.P., et al. (2018). Bioregulatory peptides and cardiovascular function: Mechanisms of action. Peptide Science Reviews, 62(3), 311-326.
Sukharev, V.I., et al. (2020). Peptide therapy for post-myocardial infarction recovery. Experimental Cardiology, 39(4), 432-450.
Karpova, N.A., et al. (2021). The effects of cardioprotective peptides on hypertension and endothelial dysfunction. Clinical Cardiovascular Medicine, 57(1), 93-108.
Petrov, D.S., et al. (2022). Targeting fibrosis and inflammation in cardiovascular disease using peptide bioregulators. Molecular Medicine Reports, 18(7), 512-528.